Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma
Sixue Liu(University of California, Los Angeles), Roger S. Lo(University of California, Los Angeles), Shirley H. Lomeli(University of California, Los Angeles), Elizabeth C. O’Quinn(Medical University of South Carolina), Cynthia Timmers(Cancer Genetics (United States)), Raymond J. Lim(University of California, Los Angeles), Chrystal M. Paulos(Medical University of South Carolina), Zhentao Yang(University of California, Los Angeles), Kostyantyn Krysan(University of California, Los Angeles), Carsten Krieg(Medical University of South Carolina), Aayoung Hong(University of California, Los Angeles), David M. Neskey(Medical University of South Carolina), Hannah M. Knochelmann(Emory University), Mary S. Richardson(University of Minnesota), Martin J. Romeo(Medical University of South Carolina), Yan Wang(Shandong Provincial QianFoShan Hospital), Joshua D. Horton(Medical University of South Carolina), Steve Dubinett(University of California, Los Angeles), Camelia Dumitras(University of California, Los Angeles)
Cited by 57
Related Papers
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
|Nature|2012|1.7k
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
|Nature|2011|1.4k
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
|Nature Communications|2012|620